March 9th, 2013
Following an Embargo Break PREVAIL Trial Won’t be Presented at ACC
Larry Husten, PHD
For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. The already complicated story behind the PREVAIL trial, which was designed to confirm the safety and efficacy of […]
March 9th, 2013
Data Sources for Young Investigators: Blogging from ACC.13
Kumar Dharmarajan, MD MBA
Several Cardiology Fellows who are attending ACC.13 in San Francisco this week are blogging for CardioExchange. The Fellows include Tariq Ahmad, Megan Coylewright, Jeremiah Depta, Kumar Dharmarajan, Payal Kohli, and Sandeep Mangalmurti. View the previous post here and the next one here. I just attended a great session entitled “Getting Access to Data: Where Can Young Investigators Get Started in Clinical Research.” The session was […]
March 9th, 2013
A Fellow Reflects on the Program and on her Progress from Observer to Educator: Blogging on ACC.13
Megan Coylewright, MD MPH
Several Cardiology Fellows who are attending ACC.13 in San Francisco this week are blogging for CardioExchange. The Fellows include Tariq Ahmad, Megan Coylewright, Jeremiah Depta, Kumar Dharmarajan, Payal Kohli, and Sandeep Mangalmurti. View the previous post here, view the next post here, and for more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important […]
March 7th, 2013
Hospitals Are Seeing Rapidly Growing Numbers of Adults with Congenital Heart Disease
Larry Husten, PHD
Hospitals are treating increasing numbers of adults with congenital heart disease, thanks to tremendous progress in treatment for this condition in recent decades. A clear picture of this dramatic change emerges in a new study, presented at the ACC in San Francisco and published simultaneously in JAMA. Jared O’Leary and colleagues analyzed data from the Nationwide […]
March 6th, 2013
The Influence of Medical School Gift Restrictions on Doctors’ Prescription Decisions
Joseph S. Ross, MD, MHS and John Ryan, MD
A new study found that gift restrictions in medical schools resulted in graduates writing fewer prescriptions of newly marketed psychiatric medications compared with older, less expensive alternatives. Might this also translate to cardiovascular agents?
March 5th, 2013
FDA Again Rejects ACS Indication for Rivaroxaban
Larry Husten, PHD
For the second time the FDA has turned down the supplemental new drug application (sNDA) for the proposed indication of rivaroxaban (Xarelto, Johnson & Johnson) to treat patients with acute coronary syndrome (ACS). Despite early hopes, the ACS indication has proved tantalizingly elusive for the drug. When the pivotal ATLAS ACS 2-TIMI 51 trial was unveiled in 2011 […]
March 4th, 2013
Veterans Study Finds HIV to Be an Independent Risk Factor for MI
Larry Husten, PHD
Although it has long been suspected that people with the HIV virus are at increased risk for cardiovascular (CV) disease, reliable data has not been available. Now a new study published online in JAMA Internal Medicine provides a much clearer picture of the relationship between CV disease and HIV. Matthew Freiberg and colleagues analyzed data from 82,459 HIV-positive and […]
March 4th, 2013
Selections from Richard Lehman’s Literature Review: March 4th
Richard Lehman, BM, BCh, MRCGP
This week’s topic is the ALDO-DHF trial, which studied the effect of spironolactone on diastolic function and exercise capacity in patients with HF with preserved EF.
March 4th, 2013
New Insights on Early Repolarization
Joseph Aloysius Walsh, MD and Donald M Lloyd-Jones, MD, ScM
A new analysis of more than 5000 CARDIA study participants explores whether the early repolarization ECG pattern has multiple phenotypes.
March 1st, 2013
ACC and HRS Release Appropriate Use Criteria for ICDs and CRTs
Larry Husten, PHD
The American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) today published appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT). The document offers an expert consensus on the appropriateness of 369 separate real-life clinical scenarios in six areas: ICDs for secondary prevention, ICDs for primary prevention, comorbidities, CRT devices, generator replacement, […]